Lack of 'editing' in microRNAs can potentially drive brain cancers

SCIENTISTS in the UK and India have observed a "significant" lack of 'editing' in microRNAs in brain tissue of brain cancer patients.

In a paper published in Nature Scientific Reports, the researchers say the finding is a 'small but important' step in our understanding of brain cancer progression, and raises possibility of using  genome engineering techniques to slow or reverse the march of the disease.

MicroRNAs are a special type of RNA molecules that do not code for proteins but participate in crucial regulatory functions. They can introduce targeted variations in organization of their building blocks (ribo-nucleotides) - a process known as 'editing'. In turn, editing can enable RNA molecules to expand their functional repertoire, a process which is vital to maintain cell diversity and help our body adapt and evolve dynamically.

Dr Arijit Mukhopadhyay, a researcher in human genetics and genomics in the School of Environment and Life Sciences, and colleagues in Dehli showed that a specific organization of these building blocks favor such targeted variations to occur, and that certain variations are decreased in patients with brain cancer which can potentially drive the disease.

Dr Mukhopadhyay and the team also examined the normal microRNA editing spectrum in 13 human tissue types and found the healthy brain to have the highest amount of editing - implicating the importance of the observed drop in case of brain cancers.

"What precisely is happening, we can't say, but with altered levels and positions of these editing events, cellular output can be significantly altered which we see in case of cancers," he says.

And he says the findings pose the question of whether biochemically we can re-establish the 'editing' process using genome engineering techniques like CRISPR targeted to specific cells to revert the biological outcome.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MRI-guided SBRT reduces side effects in prostate cancer treatment